Complementary modes of therapy with mistletoe lectin-1;Komplementare therapie mit misteilektin-1-normiertem extrakt: Lebensqualitatstabilisierung beim fortgeschrittenen kolorektalen karzinom - Fakt oder fiktion?

Medizinische Welt

Volumn 48, Issue 9, 1997, Pages 419-423

  Heiny, B M ^a   Albrecht, V ^a  

^a Onkologischen Schwerpunkt K ^*  (Austria)

Author keywords

Colorectal carcinoma; Mistletoe lectin 1; Palliation; Quality of life

Indexed keywords

LECTIN; VISCUM ALBUM LECTIN;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030845960     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methatotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9.
2. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-43.
3. Bernhard J, Castiglione M, Cerny T et al. Verbessern nicht-konventionelle Zusatztherapien die Lebensqualitat von Krebspatienten? Eine methodenkritische Literaturubersicht. Schweiz Med Wochenschr 1994; 124: 55-63.
4. Beuth J, Stoffel B, Ko HI et al. Mistellektin-1: neue therapeutische Perspektiven in der Onkologie. Onkologie 1995; 18: 36-40.
5. Beuth J, Ko HI. Tunggal L et al. Das Lektin der Mistel als Immunmodulator in der adjuvanten Tumortherapie. Dtsch Zschr Onkol 1993; 25: 73-6.
6. Bleiberg H. Role of chemotherapy for advanced colorectal cancer, new opportunities. Semin Oncol 1996; 23: 42-50.
7. Bonomi AE, Cella DF, Hahn EA et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 1996; 5: 309-20.
8. Boyle H, Clover A, Fisher P et al. Complemtary Cancer Therapy: A pilot study of patients, therapies and quality of life. Complement Therap Med 1995; 3: 129-33.
9. Cella DF, Cherin FA. Quality of life during and after cancer treatment. Compr Ther 1988; 14: 69-75.
10. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose and method of measurement. Cancer Invest 1993; 11: 327-36.
11. Celta DF, Tulsky DS, Gray G et al. Functional assessment of therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
12. Fries H, Beger HG, Kunz J et al. Treatment of advanced pancreatic cancer with mistletoe: Results of a pilot trial. Anticancer Res 1996; 18: 915-20.
13. Gabius HJ, Gabius S. Lectins and Cancer. Springer Verlag, Berlin. Heidelberg, New York 1991.
14. Gabius S, Kayser K, Gabius HJ. Analytische, immunologische und tierexperi- mentelle Voraussetzungen für die klinische Prufung der auf den Lektingehalt standardisierten Therapie. Dtsch Zschr Onkol 1991; 23: 113-9.
15. Glimelius B, Hoffman K, Olafsdottis M et al. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25: 829-35.
16. Cough IR, Dalgleish LI. What value is given to quality of life assessment by health professionals considering response to chemotherapy for advanced cancer? Cancer 1991; 68: 220-5.
17. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31: 1255-63.
18. Heiny BM, Beuth J. Mistletoe Extract Standardized for the Galactoside-specific Lectin (ML-1) Induces β-Endorphin Release and Immunopotentiation in Breast Cancer Patients. Anticancer Res 1994; 14: 1339-42.
19. Johnson JR, Temple R. Food and Drug Administration Requirements for Approval of New Anticancer Drugs. Cancer Treat Rep 1985; 69: 1155-7.
20. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study (see comments). J Clin Oncol 1995; 13: 1303-11.
21. Petioli R, Lorenzi M, Aquino A et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur J Cancer 1995; 31: 2105-8.
22. Steuer MK, Bonkowsky V, Strutz J et al. Immundefizienz bei Patienten mit Kopf-Hals-Plattenepithelkarzinomen: Eine rationale Grundlage für den adjuvanten Einsatz des Immunmodulators ML-1. Otolaryngol Nova 1994; 1: 152-9.
23. Stewart-Amidei C. Functional Assessment of Cancer Therapy Scale. J Neurosci Nurs 1995; 27: 219-20.
24. van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 1995; 31: 1193-7.
25. Tsavaris N, Foutzilas G, Markantonakis P et al. A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. J Chemother 1995; 7: 71-7.
26. Weh HJ. Systematische Chemotherapie des metastasterten kolorektalen Karzinoms. Onkologie 1995; 1: 28-35.